CA2227516A1 - Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires - Google Patents

Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires Download PDF

Info

Publication number
CA2227516A1
CA2227516A1 CA002227516A CA2227516A CA2227516A1 CA 2227516 A1 CA2227516 A1 CA 2227516A1 CA 002227516 A CA002227516 A CA 002227516A CA 2227516 A CA2227516 A CA 2227516A CA 2227516 A1 CA2227516 A1 CA 2227516A1
Authority
CA
Canada
Prior art keywords
asn
tyr
seq
po3h2
lle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227516A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Brigitte Gay
Pascal Furet
Joseph Schoepfer
Heinz Fretz
Joseph Rahuel
Giorgio Caravatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227516A1 publication Critical patent/CA2227516A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un peptide acylé, en l'occurrence un composé de formule (I). Dans cette formule, n est compris entre 0 et 15; X est un arylcarbonyle, cycloalkylcarbonyle, tricycloalkylcarbonyle, arylsulfonyle, hétérocyclylcarbonyle, hétérocyclylsulfonyle, carbamoyl(alcanoyle inférieur), aryl(alkyle inférieur)carbonyle, cycloalkyl(alkyle inférieur)carbonyle, aryl(alkyle inférieur)sulfonyle, hétérocyclyl(alkyle inférieur)carbonyle, hétérocyclyl(alkyle inférieur)sulfonyle, à condition qu'un groupe méthylène de l'un quelconque de ces radicaux alkyle inférieur puisse être remplacé par oxa, aza ou thia; hétérocyclyl(alcényle inférieur)carbonyle ou aryl(alcényle inférieur)carbonyle; ou, si Y est un groupe amine secondaire ou tertiaire, une fractions X ci-dessus, ou un alcanoyle inférieur, halo(alcanoyle inférieur), (alcoxy inférieur)carbonyle, aryl(alcoxy inférieur)carbonyle ou cycloalkyl(alcoxy inférieur)carbonyle; PTI est le radical bivalent de la tyrosine, ou de préférence de la phosphotyrosine ou encore d'une substance mimétique de la phosphotyrosine, AA est un radical bivalent d'un acide aminé naturel ou synthétique et Y est un hydroxy, un groupe protégeant l'extrémité C-terminale ou un groupe amine primaire, secondaire ou tertiaire. L'invention concerne également les sels dudit peptide. Ce composé et ses sels sont utiles pour traiter des maladies réagissant à l'inhibition de l'interaction entre une ou des protéines comprenant un ou des domaines SH2, et une protéine tyrosine kinase, ou une version modifiée d'une telle kinase.
CA002227516A 1995-08-17 1996-08-06 Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires Abandoned CA2227516A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9517060.1 1995-08-17
GBGB9517060.1A GB9517060D0 (en) 1995-08-17 1995-08-17 Acylated oligopeptide derivatives
PCT/EP1996/003473 WO1997008193A1 (fr) 1995-08-17 1996-08-06 Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires

Publications (1)

Publication Number Publication Date
CA2227516A1 true CA2227516A1 (fr) 1997-03-06

Family

ID=10779519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227516A Abandoned CA2227516A1 (fr) 1995-08-17 1996-08-06 Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires

Country Status (6)

Country Link
EP (1) EP0846127A1 (fr)
AU (1) AU6742596A (fr)
CA (1) CA2227516A1 (fr)
GB (1) GB9517060D0 (fr)
WO (1) WO1997008193A1 (fr)
ZA (1) ZA966967B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603227D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
WO1997043307A1 (fr) * 1996-05-16 1997-11-20 Warner-Lambert Company Composes inhibant l'association du recepteur pdgf et de phosphatidylinositol 3-kinase et leur utilisation
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
US7226991B1 (en) 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
WO2000056760A1 (fr) 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Derives de phenylalanine
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ATE362767T1 (de) * 1999-10-22 2007-06-15 Us Gov Health & Human Serv Hemmung der zellmotilität und angiogenese mit grb2 sh2-domäne inhibitoren
US7871981B2 (en) 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
AU2001285133A1 (en) * 2000-08-22 2002-03-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services SH2 domain binding inhibitors
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006055525A2 (fr) * 2004-11-15 2006-05-26 Ceptyr, Inc. Inhibiteurs de proteine-tyrosine-phosphatase et methodes d'utilisation de ceux-ci
CA2773661A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Derives ethers d'heteroaryles bicycliques
EP2504339A1 (fr) 2009-11-25 2012-10-03 Novartis AG Dérivés hétérocycliques d'hétéroaryles bicycliques à 6 cycles benzéniques accolés de benzène contenant de l'oxygène
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
JP2017525351A (ja) 2014-07-30 2017-09-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． 多能性幹細胞の培養用培地
JP6880001B2 (ja) * 2015-08-28 2021-06-02 ヴェンタナ メディカル システムズ， インク． ケージドハプテンを使用するホルマリン固定パラフィン包埋組織におけるタンパク質近接アッセイ
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
EP3730483B1 (fr) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Classe d'inhibiteurs de kinase dérivés de pyrimidine
EP3914698A1 (fr) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Milieux de culture pour cellules souches pluripotentes
WO2021097256A1 (fr) 2019-11-14 2021-05-20 Cohbar, Inc. Peptides antagonistes de cxcr4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
JPH09504295A (ja) * 1993-10-25 1997-04-28 パーク・デイビス・アンド・カンパニー タンパク質：ファルネシルトランスフェラーゼの置換されたテトラ‐およびペンタペプチド阻害剤
WO1996023813A1 (fr) * 1995-02-01 1996-08-08 Affymax Technologies N.V. Peptides et composes se fixant aux domaines sh2

Also Published As

Publication number Publication date
ZA966967B (en) 1997-02-17
EP0846127A1 (fr) 1998-06-10
WO1997008193A1 (fr) 1997-03-06
AU6742596A (en) 1997-03-19
GB9517060D0 (en) 1995-10-25

Similar Documents

Publication Publication Date Title
CA2227516A1 (fr) Derives oligopeptidiques acyles presentant une activite inhibant des signaux cellulaires
US6846806B2 (en) Peptide inhibitors of Hepatitis C virus NS3 protein
ES2234144T3 (es) Analogos de peptidos inhibidores de la hepatitis c.
US6774212B2 (en) Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
EP0272671B1 (fr) Aryloxy et arylacyloxy méthyl cétones comme inhibiteurs de thiol protéase
JP3203579B2 (ja) 新規なペプチダーゼ阻害剤類
TWI248444B (en) FAP-activated anti-tumour compounds
JPH09511501A (ja) ２６ｓタンパク質分解複合体とその中に含まれる２０ｓプロテアソームの阻害剤
JPH05230095A (ja) 治療薬としての新規５−アミノ−４−ヒドロキシヘキサン酸誘導体
WO1997007131A1 (fr) Oligopeptides acyles divers
ES2204713T3 (es) Inhibidores de proteasa ns3 de hcv.
JP2000503648A (ja) グルタチオンのアナログとの共有結合により束縛されたプロドラッグ
JPH05178757A (ja) トロンボスポンジン−様活性を有するペプチド及びその治療のための使用
JPH09500100A (ja) Ｅｌａｍ−１に結合するペプチド類及び化合物類
Schmittberger et al. Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins
US20070042962A1 (en) Peptide dependent upregulation of telomerase expression
HU185229B (en) Process for preparing pharmaceutically active peptides and acetates thereof
Roubini et al. Pseudopeptide analogs of substance P and leucine enkephalinamide containing the. psi.(methyleneoxy) modification: synthesis and biological activity
US6307090B1 (en) Acylated oligopeptide derivatives having cell signal inhibiting activity
US4579841A (en) Dipeptide derivatives having opiate activity
JPH07316191A (ja) アシルオキシヘキサノン酸誘導体
WO1996040759A1 (fr) Composes antiviraux de type peptidique
US6649593B1 (en) Modulators of SREBP processing
US5844078A (en) Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides
JPH02501735A (ja) 新規化合物

Legal Events

Date Code Title Description
FZDE Dead